Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
17,642,820
-
Shares change
-
+280,944
-
Total reported value, excl. options
-
$117,491,115
-
Value change
-
-$7,224,591
-
Put/Call ratio
-
125%
-
Number of buys
-
48
-
Number of sells
-
-41
-
Price
-
$6.66
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q2 2023
126 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2023.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17,642,820 shares
.
Largest 10 shareholders include FMR LLC (4,373,447 shares), STATE STREET CORP (2,072,199 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1,952,500 shares), BlackRock Inc. (1,389,229 shares), WELLINGTON MANAGEMENT GROUP LLP (1,203,344 shares), VANGUARD GROUP INC (1,128,722 shares), Artemis Investment Management LLP (895,048 shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (623,525 shares), GEODE CAPITAL MANAGEMENT, LLC (404,650 shares), and AMERIPRISE FINANCIAL INC (349,460 shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.